Annaida Technologies SA closes oversubscribed Pre-Series A

Annaida Technologies, a Vaud-based start-up company bringing magnetic resonance to the scale of cells, announces the successful closing of its oversubscribed Pre-Series A funding round.

The round, led by HEMEX, saw the participation from existing investors including Zürcher Kantonalbank (ZKB), Excellis, EFI Lake Geneva Ventures, and members of Club degli Investitori through Simon Fiduciaria. The capital raised, combined with the support from EIC Transition (Horizon Europe) and Innosuisse (Swiss Innovation Project), places Annaida in a strong position to mature its groundbreaking micro magnetic resonance platform into a commercial product.

In addition to preparing for market entry in the fertility sector, the company is generating its first revenues through research product sales. Annaida’s Embryospin platform is already being used in top ranked academic laboratories worldwide for advanced magnetic resonance research. Annaida’s proprietary technology has already demonstrated its potential in the fertility space, with additional future applications envisioned in the broader life sciences sector.

With the ongoing projects and collaborations with top ranked universities, the funds will further support product development, regulatory validation, marketing and IP to consolidate the strategic company’s position in existing and emerging markets. “These resources will help us grow our R&D activities and collaborations and establish market presence, pushing us closer to our vision of turning micro magnetic resonance into a tool that expands the boundaries of science,” said Marco Grisi, Founder & CEO of Annaida. “Specifically, by applying it to pre-implantation embryo analysis, we aim to help reduce the number of miscarriages in assisted fertility and offer a brighter future to millions of families.”

“We’ve proudly supported Annaida Technologies since its inception in 2019,” said Pascal Winnen, HEMEX representative and member of Annaida’s Board of Directors. “As an early-stage investor, we are highly impressed by the company’s progress, the wide-ranging potential of its technology, particularly in the field of human fertility, and, above all, the team’s consistent ability to meet ambitious milestones and create substantial value for shareholders.”

➡️ Source: Annaida Technologies |  📸 Marco Grisi